Table 1.
Correlation Between Serum sPD-L1 Levels and HL Patients' Clinical Characteristics
| Characteristics | Serum sPD-L1 Level |
P | |
|---|---|---|---|
| High (>25.16 ng/ml) (n=33) |
Low (≤25.16 ng/ml) (n=75) |
||
| Age | .096 | ||
| ≤35 | 15 | 47 | |
| >35 | 18 | 28 | |
| Gender | .597 | ||
| Male | 22 | 46 | |
| Female | 11 | 29 | |
| Histological type | .345 | ||
| cHL | 29 | 70 | |
| NLPHL | 4 | 5 | |
| Ann Arbor Stage | .036 | ||
| Limited | 20 | 44 | |
| Advanced | 13 | 31 | |
| B symptoms | .258 | ||
| Yes | 17 | 27 | |
| No | 16 | 48 | |
| Bulky | .258 | ||
| Yes | 5 | 6 | |
| No | 28 | 69 | |
| TR after 2 cycles of chemotherapy | .091 | ||
| CR or PR | 14 | 45 | |
| Less than PR | 19 | 30 | |
| Relapse or not | .079 | ||
| Yes | 6 | 12 | |
| No | 27 | 63 | |
Abbreviations: cHL, classical Hodgkin lymphoma; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; TR after 2 cycles of chemotherapy, treatment response after 2 cycles of chemotherapy; CR, complete response; PR, partial response; sPD-L1, soluble programmed death ligand-1.